AGTC-401

N/A

Report date: 2026/01/21 11:31:29

Base Information

Drug NameAGTC-401
Drug Alias NameAAV-PR1.7-hCNGBco vectorAAV2tYF-PR1.7-hCNGB3corAAV2tYF-PR1.7-hCNGB3rAAV2tYF-PR1.7-hCNGB3 (Applied Genetic Technologies Corporation)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionGene transferenceCyclic nucleotide-gated cation channel beta-3 stimulants
TargetsCyclic nucleotide-gated cation channel beta-3
Therapy Area/IndicationsColor Vision Defects
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApplied Genetic Technologies Corporation
China Registration ClassN/A

Develop Information

Active CompaniesApplied Genetic Technologies CorpJohnson & Johnson
Inactive CompaniesN/A
Active IndicationsColor Vision Defects
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A